Franklin Genomic Advancements ETF
HELX
1 hedge funds and large institutions have $2.23M invested in Franklin Genomic Advancements ETF in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
33% more capital invested
Capital invested by funds: $1.68M → $2.23M (+$551K)
10% less ownership
Funds ownership: 75% → 65% (-10%)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$277K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Franklin Resources
San Mateo,
California
| $2.23M | -$277K | -10,000 | -13% |
|
HELX Hedge Fund Activity: Q2 2020 in Review
1 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q2 2020, worth a combined $2.23M — up 33% from $1.68M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of HELX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Franklin Resources, cutting an estimated $277K.
- 1 institutional investor held Franklin Genomic Advancements ETF (HELX) as of Q2 2020, down from 2 in Q1 2020.
- Funds reported $2.23M of Franklin Genomic Advancements ETF stock for Q2 2020, up 33% quarter-over-quarter.
- 0 funds opened new Franklin Genomic Advancements ETF positions in Q2 2020 and 1 closed out, a net change of -1 holder.
- The largest Franklin Genomic Advancements ETF seller in Q2 2020 was Franklin Resources, an estimated $277K sold.
Based on aggregated 13F filings for Q2 2020.